WASHINGTON (AP) — Americans' confidence in the economy slumped for the fifth straight month to the lowest level since the ...

NEW YORK (AP) — U.S. stocks are drifting in mixed trading Tuesday as stronger-than-expected profits keep piling higher for ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 73 cents per share. The water and fuel pumping systems ...

HOUSTON (AP) — HOUSTON (AP) — Enterprise Products Partners L.P. (EPD) on Tuesday reported first-quarter profit of $1.39 billion. The Houston-based company said it had profit of 64 cents per share.

Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

The loans sat on banks' books for two-and-a-half years until the election of Donald Trump rapidly changed the company's fortunes. International Business Machines plans to invest $150 billion in the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...